18F-TRX Imaging for Cancer
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it excludes those taking strong inhibitors or inducers of CYP3A4. It's best to discuss your medications with the trial team.
What data supports the effectiveness of the treatment 18F-TRX for cancer?
Is 18F-TRX safe for use in humans?
How does the treatment 18F-TRX differ from other cancer treatments?
18F-TRX is a novel imaging agent used in PET scans to detect cancer by targeting specific molecular pathways, unlike the commonly used 18F-FDG which focuses on glucose metabolism. This allows for more precise imaging of certain cancer types that may not be effectively visualized with traditional methods.26111213
What is the purpose of this trial?
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Research Team
Rahul Aggarwal, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for patients with various solid tumors, including renal cell carcinoma, prostate cancer, cerebral gliomas, and malignant glioma. Participants must be eligible based on specific inclusion and exclusion criteria set by the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 18F-TRX intravenously and undergo PET/CT or PET/MRI scans
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 18F-TRX
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rahul Aggarwal
Lead Sponsor
United States Department of Defense
Collaborator